321 related articles for article (PubMed ID: 29604335)
1. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
[TBL] [Abstract][Full Text] [Related]
2. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
3. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
4. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
5. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.
Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683
[TBL] [Abstract][Full Text] [Related]
6. Chitosan Oligosaccharides Inhibit/Disaggregate Fibrils and Attenuate Amyloid β-Mediated Neurotoxicity.
Dai X; Hou W; Sun Y; Gao Z; Zhu S; Jiang Z
Int J Mol Sci; 2015 May; 16(5):10526-36. PubMed ID: 26006224
[TBL] [Abstract][Full Text] [Related]
7. Significant combination of Aβ aggregation inhibitory and neuroprotective properties in silico, in vitro and in vivo by bis(propyl)-cognitin, a multifunctional anti-Alzheimer's agent.
Hu S; Xian Y; Fan Y; Mak S; Wang J; Tang J; Pang Y; Pi R; Tsim KW; Liu F; Lin Z; Han Y
Eur J Pharmacol; 2020 Jun; 876():173065. PubMed ID: 32171792
[TBL] [Abstract][Full Text] [Related]
8. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.
Ferrera D; Mazzaro N; Canale C; Gasparini L
Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120
[TBL] [Abstract][Full Text] [Related]
9. Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
Klein AN; Ziehm T; van Groen T; Kadish I; Elfgen A; Tusche M; Thomaier M; Reiss K; Brener O; Gremer L; Kutzsche J; Willbold D
ACS Chem Neurosci; 2017 Sep; 8(9):1889-1900. PubMed ID: 28581708
[TBL] [Abstract][Full Text] [Related]
10. Testing Aβ toxicity on primary CNS cultures using drug-screening microfluidic chips.
Ruiz A; Joshi P; Mastrangelo R; Francolini M; Verderio C; Matteoli M
Lab Chip; 2014 Aug; 14(15):2860-6. PubMed ID: 24914747
[TBL] [Abstract][Full Text] [Related]
11. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
[TBL] [Abstract][Full Text] [Related]
12. Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.
Bove-Fenderson E; Urano R; Straub JE; Harris DA
J Biol Chem; 2017 Oct; 292(41):16858-16871. PubMed ID: 28842494
[TBL] [Abstract][Full Text] [Related]
13. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
Bate C; Williams A
Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
15. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.
Nieznanski K; Choi JK; Chen S; Surewicz K; Surewicz WK
J Biol Chem; 2012 Sep; 287(40):33104-8. PubMed ID: 22915585
[TBL] [Abstract][Full Text] [Related]
16. Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer's Disease Patients.
Sancesario GM; Nuccetelli M; Cerri A; Zegeer J; Severini C; Ciotti MT; Pieri M; Martorana A; Caltagirone C; Nistico R; Bernardini S
Curr Alzheimer Res; 2018; 15(7):628-636. PubMed ID: 29359669
[TBL] [Abstract][Full Text] [Related]
17. Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease.
Thapa A; Chi EY
Adv Exp Med Biol; 2015; 863():55-77. PubMed ID: 26092626
[TBL] [Abstract][Full Text] [Related]
18. Α-mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation.
Wang Y; Xia Z; Xu JR; Wang YX; Hou LN; Qiu Y; Chen HZ
Neuropharmacology; 2012 Feb; 62(2):871-81. PubMed ID: 21958557
[TBL] [Abstract][Full Text] [Related]
19. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
20. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
